The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis

Leuk Lymphoma. 2022 Jul;63(7):1651-1659. doi: 10.1080/10428194.2022.2032034. Epub 2022 Feb 8.

Abstract

Race and ethnic backgrounds affect the disease characteristics and clinical outcomes in many cancers, including acute myeloid leukemia; however, the association of race/ethnicity on myelodysplastic syndrome (MDS) is still controversial. Therefore, we aimed to study the impact of race/ethnicity on the disease characteristics and survival outcomes in patients with MDS. Adult patients with MDS diagnosed in 2004-2016 were selected using the SEER database. Race/ethnicity was categorized as non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic. Hispanic and NHB patients had significantly lower incidence rate ratio (IRR) in age group ≥01 years (p < .001) compared to NHW; however, in the age group <50 years, NHB patients had significantly higher IRR with an increased incidence rate of 49%. NHB patients had better overall survival than Hispanic and NHW patients (p < .001), even after adjusting for confounding variables. MDS have significant differences in age at diagnosis, disease risk, and survival outcomes based on racial/ethnic backgrounds.

Keywords: Myelodysplastic syndromes; ethnicity; incidence; national database; race; survival analysis.

MeSH terms

  • Adult
  • Black or African American
  • Ethnicity*
  • Hispanic or Latino
  • Humans
  • Infant
  • Middle Aged
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / epidemiology
  • Myelodysplastic Syndromes* / therapy
  • White People